PURPOSE: In recent years, there has been a shift away from performing electrophysiologic study (EPS) to guide implantable cardioverter-defibrillator (ICD) implantation with a reliance on left ventricular ejection fraction (LVEF) alone. METHODS: ICD patients were prospectively recruited from the multicentre COMFORT (Concept of Optimal Management of ventricular Fibrillation Or Very fast ventricular Tachycardia) trial. Primary prevention ICD patients (n = 260, groups 1 and 2) were compared to secondary prevention ICD patients (n = 210, group 3). Primary prevention ICDs were implanted in patients with ischemic cardiomyopathy based on LVEF ≤ 40 % and inducible ventricular tachycardia (VT) at EPS (n = 123, group 1) or impaired LVEF alone (LVEF ≤ 30 % or LVEF ≤ 35 % with NYHA class II or III; n = 137, group 2). EPS was performed in 61 % of secondary prevention ICD patients (n = 129). Patients were followed up for >12 months with a primary endpoint of spontaneous VT/ventricular fibrillation (VF). RESULTS: A significantly higher rate of spontaneous VT/VF occurred in secondary versus primary prevention ICD patients (P < 0.001) and in EPS-guided versus LVEF-guided primary prevention ICD patients (P = 0.029). At 2 years, the proportion of patients with ≥1 VT/VF episode was 24.6 ± 4.2 %, 19.9 ± 4.6 % and 37.1 ± 3.9 % for groups 1, 2 and 3, respectively. In the secondary prevention, patients who underwent EPS, VT/VF occurred in 44.4 ± 5.9 % and 14.1 ± 6.6 % with a positive versus negative result, respectively (P = 0.02). CONCLUSIONS: Secondary prevention ICD patients have more spontaneous VT/VF than primary prevention ICD patients. Secondary and primary prevention ICD patients with inducible VT at EPS have more VT/VF than patients without inducible VT or impaired LVEF alone.
PURPOSE: In recent years, there has been a shift away from performing electrophysiologic study (EPS) to guide implantable cardioverter-defibrillator (ICD) implantation with a reliance on left ventricular ejection fraction (LVEF) alone. METHODS:ICDpatients were prospectively recruited from the multicentre COMFORT (Concept of Optimal Management of ventricular Fibrillation Or Very fast ventricular Tachycardia) trial. Primary prevention ICDpatients (n = 260, groups 1 and 2) were compared to secondary prevention ICDpatients (n = 210, group 3). Primary prevention ICDs were implanted in patients with ischemic cardiomyopathy based on LVEF ≤ 40 % and inducible ventricular tachycardia (VT) at EPS (n = 123, group 1) or impaired LVEF alone (LVEF ≤ 30 % or LVEF ≤ 35 % with NYHA class II or III; n = 137, group 2). EPS was performed in 61 % of secondary prevention ICDpatients (n = 129). Patients were followed up for >12 months with a primary endpoint of spontaneous VT/ventricular fibrillation (VF). RESULTS: A significantly higher rate of spontaneous VT/VF occurred in secondary versus primary prevention ICDpatients (P < 0.001) and in EPS-guided versus LVEF-guided primary prevention ICDpatients (P = 0.029). At 2 years, the proportion of patients with ≥1 VT/VF episode was 24.6 ± 4.2 %, 19.9 ± 4.6 % and 37.1 ± 3.9 % for groups 1, 2 and 3, respectively. In the secondary prevention, patients who underwent EPS, VT/VF occurred in 44.4 ± 5.9 % and 14.1 ± 6.6 % with a positive versus negative result, respectively (P = 0.02). CONCLUSIONS: Secondary prevention ICDpatients have more spontaneous VT/VF than primary prevention ICDpatients. Secondary and primary prevention ICDpatients with inducible VT at EPS have more VT/VF than patients without inducible VT or impaired LVEF alone.
Authors: Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews Journal: N Engl J Med Date: 2002-03-19 Impact factor: 91.245
Authors: Guido H van Welsenes; Johannes B van Rees; C Jan Willem Borleffs; Suzanne C Cannegieter; Jeroen J Bax; Lieselot van Erven; Martin J Schalij Journal: Europace Date: 2011-01-05 Impact factor: 5.214
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo Journal: N Engl J Med Date: 1996-12-26 Impact factor: 91.245
Authors: Michael O Sweeney; Mark S Wathen; Kent Volosin; Ismaile Abdalla; Paul J DeGroot; Mary F Otterness; Alice J Stark Journal: Circulation Date: 2005-05-31 Impact factor: 29.690
Authors: James P Daubert; Wojciech Zareba; W Jackson Hall; Claudio Schuger; Andrew Corsello; Angel R Leon; Mark L Andrews; Scott McNitt; David T Huang; Arthur J Moss Journal: J Am Coll Cardiol Date: 2005-12-15 Impact factor: 24.094
Authors: Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman Journal: J Am Coll Cardiol Date: 2008-08-12 Impact factor: 24.094
Authors: Tobias Schupp; Ibrahim Akin; Linda Reiser; Armin Bollow; Gabriel Taton; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Uzair Ansari; Kambis Mashayekhi; Christel Weiß; Christoph Nienaber; Muharrem Akin; Martin Borggrefe; Michael Behnes Journal: Clin Res Cardiol Date: 2019-02-12 Impact factor: 5.460
Authors: Fahad Almehmadi; Andreu Porta-Sánchez; Andrew C T Ha; Hadas D Fischer; Xuesong Wang; Peter C Austin; Douglas S Lee; Kumaraswamy Nanthakumar Journal: J Am Heart Assoc Date: 2017-08-19 Impact factor: 5.501